JP2007504213A - 糖血症コントロールの処置のための併用療法 - Google Patents

糖血症コントロールの処置のための併用療法 Download PDF

Info

Publication number
JP2007504213A
JP2007504213A JP2006525215A JP2006525215A JP2007504213A JP 2007504213 A JP2007504213 A JP 2007504213A JP 2006525215 A JP2006525215 A JP 2006525215A JP 2006525215 A JP2006525215 A JP 2006525215A JP 2007504213 A JP2007504213 A JP 2007504213A
Authority
JP
Japan
Prior art keywords
glutaminyl
diabetes
pharmaceutically acceptable
thiazolidine
insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006525215A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007504213A5 (enExample
Inventor
ハンス−ウルリッヒ・デムート
コンラート・グルント
マティアス・ホフマン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prosidion Ltd
Original Assignee
Prosidion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prosidion Ltd filed Critical Prosidion Ltd
Publication of JP2007504213A publication Critical patent/JP2007504213A/ja
Publication of JP2007504213A5 publication Critical patent/JP2007504213A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
JP2006525215A 2003-09-02 2004-09-02 糖血症コントロールの処置のための併用療法 Withdrawn JP2007504213A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49953503P 2003-09-02 2003-09-02
PCT/IB2004/003082 WO2005020983A2 (en) 2003-09-02 2004-09-02 Combination therapy for glycaemic control

Publications (2)

Publication Number Publication Date
JP2007504213A true JP2007504213A (ja) 2007-03-01
JP2007504213A5 JP2007504213A5 (enExample) 2007-08-30

Family

ID=34272835

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006525215A Withdrawn JP2007504213A (ja) 2003-09-02 2004-09-02 糖血症コントロールの処置のための併用療法

Country Status (14)

Country Link
US (1) US20060287251A1 (enExample)
EP (1) EP1663200A2 (enExample)
JP (1) JP2007504213A (enExample)
KR (1) KR20060119927A (enExample)
CN (1) CN1845731A (enExample)
AU (1) AU2004267955A1 (enExample)
BR (1) BRPI0413204A (enExample)
CA (1) CA2536432A1 (enExample)
EA (1) EA200600356A1 (enExample)
IL (1) IL173844A0 (enExample)
MX (1) MXPA06002127A (enExample)
NO (1) NO20061085L (enExample)
WO (1) WO2005020983A2 (enExample)
ZA (1) ZA200601770B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0526291D0 (en) * 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
FR2896157B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
GB0623892D0 (en) * 2006-11-29 2007-01-10 Medical Res Council Technology Assay
CN102933598A (zh) * 2010-03-26 2013-02-13 诺沃—诺迪斯克有限公司 新型胰高血糖素类似物
CA2851690C (en) * 2011-10-28 2022-07-26 Sanofi-Aventis Deutschland Gmbh Treatment protocol of diabetes type 2

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19823831A1 (de) * 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
DE29924609U1 (de) * 1999-05-28 2004-04-22 Probiodrug Ag Neue Effektoren von Dipeptidylpeptidase IV
US20030139434A1 (en) * 2000-01-21 2003-07-24 Bork Balkan Combinations comprising dipeptidylpeptidase-iv inhibitor
US6890905B2 (en) * 2001-04-02 2005-05-10 Prosidion Limited Methods for improving islet signaling in diabetes mellitus and for its prevention
JP2005527504A (ja) * 2002-02-28 2005-09-15 プロシディオン・リミテッド グルタミニルを基礎するｄｐｉｖ阻害剤
EP1543023B1 (en) * 2002-09-18 2010-03-17 Prosidion Limited Secondary binding site of dipeptidyl peptidase iv (dp iv)

Also Published As

Publication number Publication date
IL173844A0 (en) 2006-07-05
WO2005020983A3 (en) 2005-07-28
CN1845731A (zh) 2006-10-11
AU2004267955A1 (en) 2005-03-10
MXPA06002127A (es) 2006-05-31
ZA200601770B (en) 2007-07-25
EP1663200A2 (en) 2006-06-07
BRPI0413204A (pt) 2006-10-03
EA200600356A1 (ru) 2006-08-25
US20060287251A1 (en) 2006-12-21
NO20061085L (no) 2006-05-31
KR20060119927A (ko) 2006-11-24
WO2005020983A2 (en) 2005-03-10
CA2536432A1 (en) 2005-03-10

Similar Documents

Publication Publication Date Title
US7241756B2 (en) Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
US7078397B2 (en) Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
US7935723B2 (en) Use of organic compounds
CA2622579C (en) Use of a dpp-iv inhibitor to reduce hypoglycemic events
KR20090038908A (ko) 대사 장애의 조합 치료
EP1894567B1 (en) Concomitant pharmaceutical agents and use thereof
JP2012092136A (ja) 哺乳動物の血糖値低下のためのジペプチジルペプチダーゼｉｖエフェクターの使用
IL139862A (en) History of thiazolidine or pyroladine as effects of dipheptidyl peptides IV and pharmaceutical preparations containing them
WO2007149797A2 (en) Use of organic compounds
KR20120016051A (ko) 제약 조성물
EA015169B1 (ru) Применение ингибиторов дипептидилпептидазы
JP2006512334A (ja) Ｄｐｐ−ｉｖ阻害剤とｐｐａｒ−アルファ化合物の組み合わせ
JP2007504213A (ja) 糖血症コントロールの処置のための併用療法
EA003303B1 (ru) Способ лечения диабета тиазолидиндионом и сульфонилмочевиной
JP4914714B2 (ja) 脂質代謝異常の予防または治療用医薬組成物
MX2008016357A (es) Uso de inhibidores de cinasa c de proteina en complicaciones diabeticas.
KR20040072027A (ko) (ｓ)-2-에톡시-3-[4-(2-[4-메탄술포닐옥시페닐]에톡시)페닐]프로판산 또는3-[4-[2-(4-ｔ-부톡시카르보닐아미노페닐)에톡시]페닐]-(ｓ)-2-에톡시 프로판산 및 인슐린을 포함하는 약학 조합물
KR20090075747A (ko) 부종의 발병을 예방, 지연 또는 감소시키기 위한 디펩티딜 펩티다제 ⅳ 억제제의 용도

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070713

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070713

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20080220